Canada

Canada has for over 45 years, had a publicly funded national healthcare system designed to ensure residents receive “reasonable access” to “medically necessary” health-care services, regardless of their financial means. However, unlike many of its European counterparts, Canada has a decentralised system, comprising of 13 separate provincial and territorial health insurance plans. These plans determine how best to organize, manage, and deliver health care within their jurisdictions, guided by common values such as equity and solidarity, and are responsible for meeting basic standards of coverage.


fluticasone furoate/umeclidinium/vilanterol (TBC)

Generic Name: fluticasone furoate/umeclidinium/vilanterol Brand Name: TBC Manufacturer: GlaxoSmithKline Inc. Indications: Chronic obstructive pulmonary disease (COPD) Manufacturer Requested Reimbursement Criteria7: For the long-term, once daily, maintenance treatment of COPD including chronic bronchitis and/or emphysema, in patients with an inadequate response to a LAMA, LABA/LAMA, or ICS/LABA, or currently on multiple […]


ozenoxacin (Ozanex)

Generic Name: ozenoxacin Brand Name: Ozanex Manufacturer: Cipher Pharmaceuticals Inc. Indications: Impetigo Manufacturer Requested Reimbursement Criteria7: ​For the topical treatment of impetigo in patients aged 2 months and older. Submission Type: New Project Status: Received Biosimilar: No Companion Diagnostics: No Fee Schedule1: Pending Submit Feedback Key Milestones2 Call for patient […]


nitisinone (Nitisinone )

Generic Name: nitisinone Brand Name: Nitisinone Manufacturer: Cycle Pharmaceuticals Ltd. Indications: Hereditary tyrosinemia type 1 Manufacturer Requested Reimbursement Criteria7: Hereditary tyrosinemia type 1 Submission Type: New Project Status: Received Biosimilar: No Fee Schedule1: Pending Submit Feedback Key Milestones2 Call for patient input posted3 December 14, 2017 Patient group input closed3 […]


eluxadoline (TBC)

Generic Name: eluxadoline Brand Name: TBC Manufacturer: Allergan Pharma Co. Indications: Irritable bowel syndrom with diarrhea Manufacturer Requested Reimbursement Criteria7: ​For the treatment of IBS-D in adults, as per the proposed indication under review by Health Canada. Submission Type: New Project Status: Pending Call For Patient Input: January 24, 2018 […]


benralizumab (Fasenra)

Generic Name: benralizumab Brand Name: Fasenra Manufacturer: AstraZeneca Canada Inc. Indications: Asthma, severe eosinophilic Manufacturer Requested Reimbursement Criteria7: For add-on maintenance treatment of adult patients with severe eosinophilic asthma who are inadequately controlled with high-dose inhaled corticosteroids (ICS) and one or more additional asthma controller(s) (e.g., LABA), if one of […]


lumacaftor/ivacaftor (Orkambi )

Generic Name: lumacaftor/ivacaftor Brand Name: Orkambi Manufacturer: Vertex Pharmaceuticals (Canada) Incorporated Indications: Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older Manufacturer Requested Reimbursement Criteria7: Treatment of cystic fibrosis (CF) in patients 6 years of age and older who are homozygous for the F508del mutation in the cystic fibrosis […]


ixekizumab (Taltz)

Generic Name: ixekizumab Brand Name: Taltz Manufacturer: Eli Lilly Canada Inc. Indications: Arthritis, psoriatic Manufacturer Requested Reimbursement Criteria7: To be reimbursed for the treatment of adult patients with active psoriatic arthritis (PsA), used alone or in combination with methotrexate, when the response to previous conventional disease-modifying antirheumatic drugs (cDMARDs) therapy […]


Levodopa / carbidopa (Drug Plan Submission) (Duodopa )

Generic Name: Levodopa / carbidopa (Drug Plan Submission) Brand Name: Duodopa Manufacturer: AbbVie Corporation Indications: Parkinson’s disease Requested Reimbursement Criteria: Not applicable. Drug plan submission. Submission Type: Resubmission Project Status: Pending Call For Patient Input: January 11, 2018 Patient Input Closed: March 2, 2018 Anticipated Date: February 8, 2018 Biosimilar: […]


abobotulinumtoxinA (Dysport Therapeutic)

Generic Name: abobotulinumtoxinA Brand Name: Dysport Therapeutic Manufacturer: Ipsen Biopharmaceuticals Canada Inc. Indications: Lower limb spasticity Requested Reimbursement Criteria: ​For the treatment of lower limb spasticity in pediatric patients 2 years of age and older. Submission Type: New Indication Project Status: Pending Call For Patient Input: January 3, 2018 Patient […]


Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza)

Generic Name: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide Brand Name: Symtuza Manufacturer: Janssen Inc. Indications: HIV-1 infection Submission Type: New Project Status: Pending Call For Patient Input: November 24, 2017 Patient Input Closed: January 22, 2018 Anticipated Date: December 29, 2017 Biosimilar: No Fee Schedule1: Pending Submit Feedback Tags infectious diseases, hiv/aids


Dolutegravir / rilpivirine (TBC)

Generic Name: Dolutegravir and rilpivirine Brand Name: TBC Manufacturer: ViiV Healthcare ULC Indications: HIV infection Submission Type: New Combination Project Status: Pending Call For Patient Input: November 23, 2017 Patient Input Closed: January 19, 2018 Anticipated Date: December 21, 2017 Biosimilar: No Fee Schedule1: Pending Submit Feedback Tags infectious diseases, […]


Dolutegravir and rilpivirine (TBC)

Generic Name: Dolutegravir and rilpivirine Brand Name: TBC Manufacturer: ViiV Healthcare ULC Indications: HIV infection Submission Type: New Combination Project Status: Pending Call For Patient Input: November 23, 2017 Patient Input Closed: January 19, 2018 Anticipated Date: December 21, 2017 Biosimilar: No Fee Schedule1: Pending Submit Feedback Tags infectious diseases, […]


buprenorphine hydrochloride (Probuphine)

Generic Name: buprenorphine hydrochloride Brand Name: Probuphine Manufacturer: Knight Therapeutics Inc. Indications: opioid drug dependence Submission Type: New Project Status: Pending Call For Patient Input: November 22, 2017 Patient Input Closed: January 18, 2018 Anticipated Date: December 20, 2017 Biosimilar: No Fee Schedule1: Pending Submit Feedback Tags mental health, addiction


fluocinolone acetate (Iluvien)

Generic Name: fluocinolone acetate Brand Name: Iluvien Manufacturer: Knight Therapeutics Inc. Indications: Diabetic macular edema (DME) Submission Type: New Project Status: Pending Call For Patient Input: November 22, 2017 Patient Input Closed: January 18, 2018 Anticipated Date: December 20, 2017 Biosimilar: No Fee Schedule1: Pending Submit Feedback Tags eye, diabetes


test for cons ()

Pre Noc Submission NOC Date Submission Date (Target Date) Prioritization Requested Stakeholder Input Deadline (target date based on target submission date) ‡ Check-point meeting (target date) pERC Meeting (target date) Initial Recommendation Issued (target date) Feedback Deadline (target date) ‡ pERC Reconsideration Meeting (target date) Final Recommendation Issued (target date) […]


Screening for Chlamydia trachomatis and Neisseria gonorrhoeae During Pregnancy

Neisseria gonorrhoea (GC) and Chlamydia trachomatis (CT) are common, reportable, sexually transmitted infections of significant public health concern. Although GC and CT infection can be asymptomatic, the health risks to women include pelvic inflammatory disease, tubal infertility, ectopic pregnancy, endometriosis, and chronic pelvic pain. Of additional importance is that, in […]


tenofovir alafenamide (Vemlidy)

Generic Name: tenofovir alafenamide Brand Name: Vemlidy Manufacturer: Gilead Sciences Canada, Inc. Indications: Hepatitis B, chronic Submission Type: New Project Status: Received Biosimilar: No Fee Schedule1: Pending Submit Feedback Key Milestones2 Call for patient input posted3 August 30, 2017 Patient group input closed3 October 20, 2017 Patient input summary sent […]


sebelipase alfa (Kanuma)

Generic Name: sebelipase alfa Brand Name: Kanuma Manufacturer: Alexion Pharmaceuticals Indications: Lysosomal acid lipase deficiency Submission Type: New Project Status: Pending Call For Patient Input: October 4, 2017 Patient Input Closed: November 23, 2017 Anticipated Date: November 2, 2017 Biosimilar: No Fee Schedule1: Pending Submit Feedback


ocrelizumab (Ocrevus)

Generic Name: ocrelizumab Brand Name: Ocrevus Manufacturer: Hoffman-La Roche Limited Indications: Primary progressive multiple sclerosis Project Status: Pending Call For Patient Input: September 27, 2017 Patient Input Closed: November 16, 2017 Anticipated Date: October 26, 2017 Biosimilar: No Fee Schedule1: Pending Submit Feedback


Insulin lispro (Admelog )

Generic Name: Insulin lispro Brand Name: Admelog Manufacturer: sanofi-aventis Canada Inc. Indications: Diabetes mellitus, Type 1 & 2 Submission Type: New Project Status: Pending Call For Patient Input: September 27, 2017 Patient Input Closed: November 16, 2017 Anticipated Date: October 26, 2017 Biosimilar: No Fee Schedule1: Pending Submit Feedback